Global Bioengineered Protein Drugs Market Size By Disease (Cancer, Diabetes), By Method Of Drug Delivery (Novel approaches, Traditional methods), By Drug Types (Peptide hormones, Recombinant protein drugs), By Technology (Genetic engineering, Pharming), By End-User (CROs, Research institutes), By Geographic Scope And Forecast

Bioengineered Protein Drugs Market Size And Forecast

Bioengineered Protein Drugs Market size was valued at USD 340.1 Billion in 2023 and is projected to reach USD 560.9 Billion by 2030, growing at a CAGR of 8.8% from 2024 to 2030.

So, you know how diseases like diabetes, cancer, heart disease, and asthma are becoming more common? Well, that's a big reason why the market for bioengineered protein drugs is growing. These drugs are pretty popular because they tend to have fewer side effects. Doctors are already recommending them, which is really pushing the market forward. Plus, with everyone focusing more on preventive care, there's a bigger chance to sell these drugs as vaccines. If you want a complete picture of everything that's going on, check out the Global Bioengineered Protein Drugs Market report. It breaks down all the important parts – the key segments, trends, what's helping and hurting the market, who the competition is, and all the things that are making a difference.

Global Bioengineered Protein Drugs Market Definition

Bioengineering is the implementation of engineering techniques and materials in the field of biology. Proteins are polymers of amino acids that play a key role in the body’s function. Genetic engineering is used to create bioengineered proteins. They’re also known as recombinant proteins. Bioengineered protein medications are used to treat human injuries, hormonal disorders, cancers, and chronic diseases like asthma, diabetes, and heart disease, among others.

Proteins are essential for the maintenance of an organism’s structural and functional aspects. A protein molecule is made up of a long chain of amino acids that regulates all biological functions of the body such as DNA replication, metabolic reactions, and other vital expressive functions. Due to their safety, specificity, bioreactivity, and rate of success in curing life-threatening diseases and injuries, these special drugs are gaining traction in the pharmaceutical industry.

Global Bioengineered Protein Drugs Market Overview

The rising prevalence of chronic diseases, combined with the biopharmaceuticals industry’s extensive technological progress, have emerged as key driving forces for the bioengineered protein therapeutics market. The rise in the prevalence of diseases like diabetes, cancer, asthma, heart disease, and others is a major driving force in the Bioengineered Protein Drugs Market. According to WHO, the population having diabetes globally will reach 366 million by 2030, positively influencing the rapid growth of the market.

Bioengineered protein drugs are said to have better PK and PD because they are target specific and highly efficient. Other factors driving the growth of this market include technological advancements in bioengineering drug proteins, targeted drug delivery methods for effective treatment, and rising healthcare expenditure. However, the complications involved in disease treatment with bioengineered protein drugs, as well as the ever-increasing cost of drugs are likely to hinder the growth of the global market during the forecast period.

Also, the high cost of bioengineered protein drugs limits the market’s growth. Furthermore, complications associated with the treatment of certain illnesses with bioengineered drugs impede the global expansion of bioengineered protein drugs. However, recognizing the booming market for bioengineered protein drugs, market participants are increasing their investments in the development of a diverse range of products such as vaccines, therapeutic proteins, and monoclonal antibodies.

Global Bioengineered Protein Drugs MarketSegmentation Analysis

The Global Bioengineered Protein Drugs Market is segmented on the basis of Disease, Method Of Drug Delivery, Drug Types, Technology, End-User, And Geography.

Bioengineered Protein Drugs Market, By Disease

• Cancer
• Diabetes
• Blood disorders
• Skin diseases
• Neurodegenerative diseases
• Heart diseases
• Infectious diseases
• Respiratory diseases
• Autoimmune disorders
• Congenital diseases
• Arthritis
• Others

Based on Disease, The market is segmented into Cancer, Diabetes, Blood disorders, Skin diseases, Neurodegenerative diseases, Heart diseases, Infectious diseases, Respiratory diseases, Autoimmune disorders, Congenital diseases, Arthritis, and Others. Increased incidences of Cancer and Diabetes throughout the globe make cancer and diabetes sub-segment the highest revenue earning segment and is expected to continue growing.

As per the National Health Commission, more than 2,000 people died in China in August 2019 from contagious diseases like plague and cholera. Such a high death rate encourages the use of therapeutics, particularly in highly populated countries like China and India. An increase in the geriatric population also impacts the growth positively for the Arthritis segment growth. Other sectors are also growing due to the factors like lesser side effects, better absorbability, ease of dosing, and many others.

Bioengineered Protein Drugs Market, By Method Of Drug Delivery

• Novel approaches
• Traditional methods

Based on Method Of Drug Delivery, The market is segmented into Novel approaches and Traditional methods. The bioengineered protein drugs industry is bifurcated into novel approaches, and traditional practices on the basis of drug delivery methods. Traditional procedures are used to hold the highest market share. But, in recent times due to heavy R&D investments and shifting toward newer delivery methods, novel technics are getting more boost. A few of the difficulties related to parenteral administration have been addressed by PEGylation and polymeric depot technologies.

Although much investigation has been concentrated on non-invasive paths like peroral, pulmonary, and transdermal for protein and peptide delivery in order to increase patient compliance, their delivery through the use of non-invasive routes remains a challenge due to enzymatic instability and poor absorption. The pulmonary route has had some success, as evidenced by the FDA’s recent approval of inhalable insulin. The development of such an oral dose for protein therapeutics remains the most desirable, but also the most difficult.

Bioengineered Protein Drugs Market, By Drug Types

• Peptide hormones
  1. Insulin
  2. Growth hormones
  3. Luteinizing hormones and follicle stimulating hormones
  4. Erythropoietin
• Recombinant protein drugs
• Vaccines
  1. Live attenuated
  2. Toxoid
  3. Inactivated or killed vaccines
  4. Subunit or conjugate
• Therapeutic enzymes
  1. Digestive
  2. Metabolic
  3. Other enzymes
• Cytokines
  1. Interleukins
  2. Interferons
  3. Colony stimulating factors
• Peptide antibiotics
• Monoclonal antibodies
• Replacement proteins
• Blood products
  1. Antithrombin
  2. Immune globulins
  3. Thrombin
  4. C1 esterase inhibitor
  5. Coagulation factors
  6. Alpha 1-protease inhibitor

Based on Drug Types, The market is segmented into Peptide hormones, Recombinant protein drugs, Vaccines, Therapeutic enzymes, Cytokines, Peptide antibiotics, Monoclonal antibodies, Replacement proteins, and Blood products. The bioengineered protein drugs industry is bifurcated into peptide hormones, recombinant protein drugs, therapeutic enzymes, vaccines, cytokines, peptide antibiotics, replacement proteins, monoclonal antibodies, and blood products on the basis of drug types. Due to its increased use in therapies for cancer, autoimmune diseases, and inflammations, monoclonal antibodies are the most appealing drug type.

Bioengineered Protein Drugs Market, By Technology

• Bioreactors and microbial cell fermentation
• Fractionation
• Genetically modified organisms
• Genetic engineering
• Pharming
• Cell culture
• Others

Based on Technology, The market is segmented into Bioreactors and microbial cell fermentation, Fractionation, Genetically modified organisms, Genetic engineering, Pharming, Cell culture, and Others. The bioengineered protein drugs industry is bifurcated into bioreactors and microbial cell fermentation, genetic engineering, fractionation, GMOs or genetically modified organisms, pharming, cell culture and others on the basis of technology. Technology advancements like GMOs or genetically modified organisms as well as cell cultures are accelerating market growth. Those two markets are having most of the market share.

Bioengineered Protein Drugs Market, By End-User

• CROs
• Research institutes
• Pharmaceutical and biotechnology companies

Based on End-User, The market is segmented into CROs, Research institutes, and Pharmaceutical and biotechnology companies. The Pharmaceutical and biotechnology companies segment is expected to grow highly due to huge R&D investments put in by them. For example, Eli Lilly invested nearly USD 7.03 billion in 2021, while Pfizer spent approximately USD 13.8 billion.

Bioengineered Protein Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Bioengineered Protein Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America has appeared as the market leader in the field and also is expected to grow rapidly in the future. The rising prevalence of chronic diseases, as well as the emergence of technically sophisticated protein therapeutics, have emerged as important key driving forces for the market in this region.

During the forecast period, Asia Pacific is expected to exceed North America in the worldwide Bioengineered Protein Drugs Market. The increasing prevalence of chronic disorders, the expansion of healthcare facilities in several Asian economies, and massive investments by key market players are driving the growth of the Asia Pacific Bioengineered Protein Drugs Market. Due to the upsurge of biosimilars in this region, Europe is expected to experience slow growth in the market throughout the forecast period.

Key Players

The “Global Bioengineered Protein Drugs Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Baxter Healthcare, Abbott Laboratories, Bayer Healthcare Pharmaceuticals, Amgen, Eli Lilly and Co., Fresenius Kabi USA, GlaxoSmithKline, Johnson & Johnson, Hoffman-la-Roche, and Merck & Co. Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April 2022 – Satellite Bio debuts a novel approach toward bioengineering tissues. Synthetic biology, regenerative medicine, cell therapy, cell biology, as well as tissue engineering are all areas of expertise for this company.
• January 2022 – Altos Labs was established as a new biotechnology company dedicated to unraveling the complex biology of cellular rejuvenation programming.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We'll break down the market using both numbers and less tangible things like consumer behavior, dividing it all up into segments. You'll get actual market value figures (in USD Billion) for each of those segments and sub-segments. Plus, we'll pinpoint which region and segment we think will grow the fastest and ultimately lead the pack. We'll also dig into how each region consumes the product/service and what's influencing the market there. Expect a competitive landscape view, including a ranking of the big players and details on their new stuff, collaborations, expansions, and acquisitions over the last five years. Company profiles are in there too, giving you an overview, insights, product comparisons, and SWOT analysis for the major players. We'll also give you our take on the industry's current and future state, considering recent happenings, growth opportunities, and the challenges facing both up-and-coming and established regions. Expect a thorough look at the market through Porter's five forces analysis and a peek into the Value Chain. Finally, we'll cover the market's dynamics and potential for growth in the coming years. Oh, and we'll throw in 6 months of analyst support after you buy.

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.